clinical trial · NCT07303777
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
Atom Therapeutics Co., Ltd·phase2·not yet recruiting·n = 200
Atherosclerosis Cardiovascular DiseaseASCVDASCVD ManagementABP-745 Dose APlaceboABP-745 Dose BABP-745 Dose C
brief summary
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
started
Apr 1, 2026
primary completion
Jan 1, 2028
completion
Apr 1, 2028
last updated
Apr 9, 2026
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol